Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles Infusion Treatment for Acute Respiratory Distress Syndrome: A Phase I/II Clinical Trial
Latest Information Update: 02 Aug 2024
At a glance
- Drugs DB-001 (Primary)
- Indications Adult respiratory distress syndrome
- Focus Adverse reactions; Therapeutic Use
- Acronyms EXIT-ARDS
- Sponsors Direct Biologics
- 29 Jul 2024 Status changed from not yet recruiting to withdrawn prior to enrolment due to change in development plan.
- 02 May 2023 Planned End Date changed from 1 Dec 2023 to 31 Dec 2024.
- 02 May 2023 Planned primary completion date changed from 2 Sep 2023 to 31 Dec 2024.